Jazz Pharmaceuticals gained retail buzz after the FDA granted accelerated approval to Modeyso, the first treatment for a rare brain tumor with H3 K27M mutation. Based on 50-patient trial data, the drug showed a 22% response rate. While some side effects were reported, experts called the approval a milestone. Stock sentiment turned 'extremely bullish'.